Abstract:Patients with SAP complicated with acute kidney injury have higher mortality than patients with SAP alone.1 CT is invaluable for the management of patients with severe acute pancreatitis. Although intravenous administration of radiographic contrast media may be helpful or essential for adequate imaging, the potential complication of contrast-induced nephropathy (CIN) is a significant concern. To the best of our knowledge, there have been no previous reported studies assessing the extent to which IV-administered contrast media for CT might affect subsequent renal function in patients with severe acute pancreatitis in an ICU setting. A retrospective analysis of a prospectively collected database was performed. The study group consisted of 107 patients who underwent Contrast-enhanced computed tomography (CECT). The demographic and clinical characteristics and medical test values from four days before to four days after scanning were logged. The inclusion criteria for SAP were defined according to the Atlanta criteria.2 Patients with SAP complicated with acute kidney injury were excluded in this study. CIN is typically defined as an increase in serum creatinine of 25 per cent over baseline, or an absolute increase of 0.5 mg/dL (44.2 mmol/L), within 48 hours of contrast administration.3 Iodinated nonionic contrast material was administered at a rate of 2.5 to 3 mL/sec for a total of 100 mL with a high-pressure autoinjector. CT enhancement was carried out in the pancreatic phase, and the scanning time was 35 seconds after injection of contrast materials. The serum level of blood urea nitrogen (BUN) was 5.250 mmol/L (±2.673 [SEM] mmol/L) on day 0, and it significantly increased to 5.289 mmol/L (±3.496 [SEM] mmol/L, P < 0.05) on the third day after CT scan. On the fourth day after CT scan, the difference was still significant when compared with the level on day 0 (5.364 ± 3.635 mmol/L vs 5.250 ± 2.673 mmol/L, P < 0.05). Average creatinine levels trended up slightly. Figure 1 summarizes the overall changes in creatinine levels from baseline to the fourth day after CT scan. However, there was no difference between the mean values of the four days before CT scan and within four days after CT scan. The value of cystatin C has a similar trend to the value of creatinine. Other clinical measurements, including alanine aminotransferase and albumin, were slightly lower than the value before CT scan. However, there was no difference either (Fig. 1). The incidence of contrast-induced nephropathy observed in this study using the previously described definitions was 8.41 per cent (9 patients in 107), and the differences between the CIN group and the nonCIN group are presented in Table 1. In patients with CIN, baseline cystatin C and hematocrit levels were significantly higher (1.466 ± 1.373 vs 3.231 ± 2.148 and 0.311 ± 0.075 vs 0.354 ± 0.10, P 4 0.016 and P 4 0.004, respectively). Hospital mortality was significantly higher in the CIN group (6.12% vs 33.33%, P < 0.05). The average Acute Physiology and Chronic Health Evaluation (APACHE II) scores of patients on admission were significantly higher in the CIN group (10.57 ± 1.969 vs 13.22 ± 3.734, P 4 0.003). Hospital duration was much shorter in the CIN group (38.29 vs 19.71, P < 0.05). Other clinical variables were no significantly different between the two groups. The logistic regression analysis of CIN indicated that significant differences existed between SAP patients with and without CIN in the following aspects: APACHE II score, baseline cystatin C, and serum hematocrit. The results correlate well with the statistical results shown in Table 1, which also suggest differences in these three parameters between the CIN and non-CIN groups. The risk of CIN from CECT in patients with SAP was associated with serum cystatin C Address correspondence and reprint requests to Weiqin Li, M.D., Department of General Surgery, Jinling Hospital, 305 Zhong Shan East Road, Nanjing, China 210002. E-mail: wsizhen@ 126.com.

Effect of IV Contrast Medium on Renal Function in Patients with Severe Acute Pancreatitis Undergoing Contrast-Enhanced CT in ICU

Correlation Analysis of Computed Tomography Imaging Score with the Presence of Acute Kidney Injury in Severe Acute Pancreatitis

Is intravenous iodinated contrast medium administration really harmful in hospitalized acute kidney injury patients: a propensity score–matched study

Risk and harm of contrast induced nephropathy in critically ill patients

Clinical Outcomes of Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized Study to Analyze the Effect of Hydration and Acetylcysteine

Contrast Volume During Primary Percutaneous Coronary Intervention and Subsequent Contrast-Induced Nephropathy and Mortality

Effect of the low-osmolality nonionic contrast media on renal function in patients undergoing coronary intervention: a prospective study

Acute Kidney Injury in Patients with Nephrotic Syndrome Undergoing Contrast-Enhanced CT for Suspected Venous Thromboembolism: a Propensity Score-Matched Retrospective Cohort Study

Contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Cumulative Iodinated Contrast Exposure for Computed Tomography During Acute Kidney Injury and Major Adverse Kidney Events

A Prospective Study on the Risk of Contrast Induced Nephropathy in the Patients Who Underwent Contrast-Enhanced CT Examination

Patients with Different Stages of Chronic Kidney Disease Undergoing Intravenous Contrast-Enhanced Computed Tomography—The Incidence of Contrast-Associated Acute Kidney Injury

Epidemiology of contrast-induced nephropathy after computerized tomography

Clinical Study of Contrast-induced Nephropathy in Inpatients in Cardiology Department After Coronaryartery Intervention

Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration.

Clinical study of contrast induced nephropathy in patients undergoing coronary intervention.

Contrast-induced Nephropathy in 532 Patients Undergoing Coronary Intervention

Role of Serum Cystatin C in the Prediction of Contrast-Induced Nephropathy after Intra-Arterial Interventions

Incidence of contrast-associated acute kidney injury: a prospective cohort

Could serum cystatin C be employed in diagnosing contrast-induced nephropathy after nonemergency endovascular therapy with peripheral arterial diseases?

Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast